NLRC5/MHC class I transactivator is a target for immune evasion in cancer
dc.creator | Yoshihama, Sayuri | |
dc.creator | Roszik, Jason | |
dc.creator | Downs, Isaac | |
dc.creator | Meissner, Torsten | |
dc.creator | Vijayan, Saptha | |
dc.creator | Chapuy, Bjoern | |
dc.creator | Sidiq, Tabasum | |
dc.creator | Shipp, Margaret | |
dc.creator | Lizee, Gregory | |
dc.creator | Kobayashi, Koichi | |
dc.date.accessioned | 2019-10-10T21:11:13Z | |
dc.date.available | 2019-10-10T21:11:13Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 0027-8424 | |
dc.identifier.issn | 0744-2831 | |
dc.identifier.issn | 1091-6490 | |
dc.identifier.uri | https://hdl.handle.net/1969.1/183157 | |
dc.format.extent | 1 | en |
dc.publisher | Proceedings of the National Academy of Sciences of the United States of America | |
dc.relation.ispartof | 1foldr Import 2019-10-08 Batch 11 | en |
dc.relation.uri | 10.1073/pnas.1602069113 | en |
dc.title | NLRC5/MHC class I transactivator is a target for immune evasion in cancer | en |